Journey to student empowerment : the 65th Street Corridor Community Collaborative Project

The 65th Street Corridor Community Collaborative Project (65th Street Project) is a high-impact and multi-component community mobilization effort aimed at increasing student academic achievement, fostering student leadership, and improving parent participation for disadvantaged children living in neighborhoods where gang violence, a lack of access to resources and low civic engagement create a need for innovative, culturally competent strategies. The Project serves 7th -12th grade schools in Sacramento\u27s Oak Park neighborhood, a low-income and diverse community that is adjacent to the University campus. The 65th Street Project is a service-learning organization that collaborates with Hiram Johnson High School and Will C. Wood Middle School; both located in an underserved, low income, and multi-ethnic community. The two projects at these schools are the mentoring program, and a bridge program . Since the inception of the mentoring program in 2002, over 1,800 Sacramento State students have served approximately 23,500 community members, primarily providing tutoring services to students in need. The bridge program brings 7th - 12th graders and their parents to the Sacramento State campus and, over the last 12 years, has brought over 3,000 students and parents to the university, motivating a number of students to focus on the future of their education. In light of the 65th Street Project, the panel will examine the historical development of the Project; as well as the leadership development of the student staff, the bridge program, and the presentation of US History to 7th Grade students centered around their ethnic experience

The Wayne Maeda Asian American Studies Archive : an opportunity to serve the Sacramento State Campus community & develop student leadership

Wayne Maeda, as a student was one of the founders of the Asian American Studies Program (AAS) at Sacramento State University. For 42 years, he was the primary professor for AAS. When Wayne passed away in February 2013, he donated his private library and collection to Ethnic Studies. In response to his wishes Dr. Mark (also a pioneer in the founding of AAS) created the Wayne Maeda Asian American Studies Archive to serve university students, faculty, researchers, and the community-at-large. The panel will explore the creation of the Archive, the Archive as it is today, the role of students, community partnerships, and its outreach programs locally, regionally, nationally and international. The foundations of the Archive are its four components; Japanese Americans in California, Filipinos in the United States, Korean Americans in California, and Hmong Americans in the U.S. The Hmong American/Hmongs in Southeast Asia collections and outreach programs will be in scope national and international. In conclusion, the panel, History, Memory, Identity: Building the Wayne Maeda Asian American Studies Archive, will examine the historical development and purpose. There will also be specific details about the exhibit created by the Archive. The three events that were provided by the Archive and the partnerships will also be elaborated. Lastly, it exams how an Archive can be a Service-Learning tool for California State University, Sacramento students, and other Asian American student groups. Future projects will also be briefly Paper presented

The Aluminum Falcon: a Low Cost Modern Commercial Transport

The American Institute of Aeronautics and Astronautics (AIAA) released a Request For Proposal (RFP) in the form of an undergraduate design competition for a 153 passenger jet transport with a range of 3,000 nautical miles. The primary requirement for this aircraft was low cost, both in acquisition and operation, with a technology availability date of the year 2000. This report presents the Non-Solo Design Group's response to the RFP, the Aluminum Falcon (AF-1). Non-Solo's approach to development was to take the best elements of seven individual preliminary designs, then combine and refine them. The resulting aircraft meets or exceeds all requirements of both the RFP and the Federal Aviation Administration (FAA). Highlights include a revolutionary wing planform, known as an M-wing, which offers many advantages over a conventional aft swept wing. For example, the M-wing lessens the travel in the aircraft center of gravity caused by fuel being stored in the wing. It also reduces the amount of torque imposed on the center wing box because more of the lifting load acts near the fuselage joint, rather than behind it. In essence, the M-wing offers the best of both worlds: using a forward swept wing root places the aerodynamic center of the wing further forward and allows the landing gear to be placed without the use of a yahudi. At the same time, with the outboard section swept backward the tip retains an amount of aeroelastic dampening that is lost on a completely forward swept wing. The result is a wing which has many advantages of a straight, unswept wings without the severe compressibility effects at high Mach numbers. Other highlights include judicious use of composites, giving recognition to the importance of weight and its effect on aircraft cost and performance, and an advanced passenger entertainment system which can be used as a source of revenue for the airlines. This aircraft meets the low-cost doctrine with an acquisition cost of $29 million and a direct operating cost of 3.5 cents per seat mile. The AF-1 incorporates new ideas with existing technology to result in an aircraft that will retain market viability well into the next century

Evaluation of Pharmaceutical Compounding Training in the Australian Undergraduate Pharmacy Curricula

Introduction: In recent decades the role of the Australian community pharmacist hasevolved to focus primarily on pharmaceutical care provision. Despite this, compounding remainsan important product service offered by pharmacists. The aim of this study was to qualitativelydescribe the current integration of training in compounding within Bachelor of Pharmacy courses inAustralia. Methods: The Australian Health Practitioner Regulatory Agency website was searchedto identify eligible university courses. Subsequently, the educational providers’ homepages wereconsulted, and Bachelor of Pharmacy handbooks and curricula perused. All relevant informationregarding training in compounding was extracted. Results: In total, 16 Bachelor of Pharmacy courseswere identified. All of these contain compounding training in their curricula, including laboratoryclasses. Most curricula have units specifically dedicated to compounding and drug formulation.Three universities offer a curriculum which is organ-systems based, and include compoundingrelevant to the individual organ systems. Discussion and Conclusions: In Australia, the training incompounding is well integrated into pharmacy curriculum and is more emphasised than in manyother developed countries. This is congruent with the International Pharmaceutical Federation’sneeds-based approach to local pharmacy education. In Australia there is a need for pharmacists toroutinely dispense simple compounded products. Further research is required to evaluate Australianpharmacy graduates’ compounding abilities and how best to promote the achievement of the requiredknowledge and skills to enable simple compounding

Pharmacists' Perspectives on the Use of My Health Record

Background: My Health Record (MHR) is a relatively new nationwide Australian digitalhealth record system accessible by patients and a range of healthcare professionals. Pharmacists willbe key contributors and users of the MHR system, yet little is known about the perceived barriers andbenefits of use. (2) Objective: To explore pharmacists’ perspectives related to potential benefits andbarriers associated with use of MHR. (3) Methods: An online survey was developed and face-validated.The survey was advertised to Australian pharmacists on pharmacy professional bodies’ websites. Thiswas a cross-sectional study using an anonymous questionnaire. Descriptive statistics were used todescribe the distribution of the data. Chi-square, Kendall’s tau coefficient (tau-c) and Kruskal–Wallistests were used to examine the relationships where appropriate. (4) Results: A total of 63 pharmacistscompleted the survey. The majority of respondents worked in a metropolitan area (74%), and themost common workplace setting was community pharmacy (65%). Perceived benefits identifiedby responders include that the use of MHR would help with continuity of care (90%), and that itwould improve the safety (71%) and quality (75%) of care they provided. Importantly, more thanhalf of pharmacists surveyed agreed that MHR could reduce medication errors during dispensing(57%) and could improve professional relationships with patients (57%) and general practitioners(59%). Potential barriers identified by pharmacists included patients’ concerns about privacy (81%),pharmacists’ own concern about privacy (46%), lack of training, access to and confidence in using thesystem. Sixty six percent of respondents had concerns about the accuracy of information containedwithin MHR, particularly among hospital and general practice pharmacists (p = 0.016) and almosthalf (44%) had concerns about the security of information in the system, mainly pharmacists workingat general practice and providing medication review services (p= 0.007). Overall satisfaction withMHR varied, with 48% satisfied, 33% neither satisfied nor dissatisfied, and 19% dissatisfied, witha higher satisfaction rate among younger pharmacists (p = 0.032). (5) Conclusions: Pharmacistsconsidered that the MHR offered key potential benefits, notably improving the safety and quality ofcare provided. To optimize the use of MHR, there is a need to improve privacy and data securitymeasures, and to ensure adequate provision of user support and education surrounding the ability tointegrate use of MHR with existing workflows and software

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and signaling demands of the cell by increasing mitochondrial biogenesis and mitochondrial protein translation. Blocking mitochondrial protein synthesis through genetic and chemical approaches kills human AML cells at all stages of development in vitro and in vivo. Tigecycline is an antimicrobial that we found inhibits mitochondrial protein synthesis in AML cells. Therefore, we conducted a phase 1 dose-escalation study of tigecycline administered intravenously daily 5 of 7 days for 2 weeks to patients with AML. A total of 27 adult patients with relapsed and refractory AML were enrolled in this study with 42 cycles being administered over seven dose levels (50-350 mg/day). Two patients experienced DLTs related to tigecycline at the 350 mg/day level resulting in a maximal tolerated dose of tigecycline of 300 mg as a once daily infusion. Pharmacokinetic experiments showed that tigecycline had a markedly shorter half-life in these patients than reported for noncancer patients. No significant pharmacodynamic changes or clinical responses were observed. Thus, we have defined the safety of once daily tigecycline in patients with refractory AML. Future studies should focus on schedules of the drug that permit more sustained target inhibition

A Detailed Observational Analysis of V1324 Sco, the Most Gamma-Ray Luminous Classical Nova to Date

It has recently been discovered that some, if not all, classical novae emit GeV gamma rays during outburst, but the mechanisms involved in the production of the gamma rays are still not well understood. We present here a comprehensive multi-wavelength dataset---from radio to X-rays---for the most gamma-ray luminous classical nova to-date, V1324 Sco. Using this dataset, we show that V1324 Sco is a canonical dusty Fe-II type nova, with a maximum ejecta velocity of 2600 km s$^{-1}$ and an ejecta mass of few $\times 10^{-5}$ M$_{\odot}$. There is also evidence for complex shock interactions, including a double-peaked radio light curve which shows high brightness temperatures at early times. To explore why V1324~Sco was so gamma-ray luminous, we present a model of the nova ejecta featuring strong internal shocks, and find that higher gamma-ray luminosities result from higher ejecta velocities and/or mass-loss rates. Comparison of V1324~Sco with other gamma-ray detected novae does not show clear signatures of either, and we conclude that a larger sample of similarly well-observed novae is needed to understand the origin and variation of gamma rays in novae.Comment: 26 pages, 13 figure

A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate

Introduction: The objective of this guideline is to outline the appropriate use of methylprednisolone sodium succinate (MPSS) in patients with acute spinal cord injury (SCI). Methods: A systematic review of the literature was conducted to address key questions related to the use of MPSS in acute SCI. A multidisciplinary Guideline Development Group used this information, in combination with their clinical expertise, to develop recommendations for the use of MPSS. Based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation), a strong recommendation is worded as "we recommend," whereas a weaker recommendation is indicated by "we suggest." Results: The main conclusions from the systematic review included the following: (1) there were no differences in motor score change at any time point in patients treated with MPSS compared to those not receiving steroids; (2) when MPSS was administered within 8 hours of injury, pooled results at 6- and 12-months indicated modest improvements in mean motor scores in the MPSS group compared with the control group; and (3) there was no statistical difference between treatment groups in the risk of complications. Our recommendations were: (1) "We suggest not offering a 24-hour infusion of high-dose MPSS to adult patients who present after 8 hours with acute SCI"; (2) "We suggest a 24-hour infusion of high-dose MPSS be offered to adult patients within 8 hours of acute SCI as a treatment option"; and (3) "We suggest not offering a 48-hour infusion of high-dose MPSS to adult patients with acute SCI." Conclusions: These guidelines should be implemented into clinical practice to improve outcomes and reduce morbidity in SCI patients

A clinical practice guideline for the management of patients with acute spinal cord injury and central cord syndrome: recommendations on the timing (<= 24 hours versus > 24 hours) of decompressive surgery

Objective: To develop recommendations on the timing of surgical decompression in patients with traumatic spinal cord injury (SCI) and central cord syndrome. Methods: A systematic review of the literature was conducted to address key relevant questions. A multidisciplinary guideline development group used this information, along with their clinical expertise, to develop recommendations for the timing of surgical decompression in patients with SCI and central cord syndrome. Based on GRADE, a strong recommendation is worded as "we recommend," whereas a weak recommendation is presented as "we suggest." Results: Conclusions from the systematic review included (1) isolated studies reported statistically significant and clinically important improvements following early decompression at 6 months and following discharge from inpatient rehabilitation; (2) in one study on acute central cord syndrome without instability, a marginally significant improvement in total motor scores was reported at 6 and 12 months in patients managed with early versus late surgery; and (3) there were no significant differences in length of acute care/rehabilitation stay or in rates of complications between treatment groups. Our recommendations were: "We suggest that early surgery be considered as a treatment option in adult patients with traumatic central cord syndrome" and "We suggest that early surgery be offered as an option for adult acute SCI patients regardless of level." Quality of evidence for both recommendations was considered low. Conclusions: These guidelines should be implemented into clinical practice to improve outcomes in patients with acute SCI and central cord syndrome by promoting standardization of care, decreasing the heterogeneity of management strategies, and encouraging clinicians to make evidence-informed decisions